The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Dalester,
A very well crafted post that captures all the elements of what has been discussed on the subject of Trish and now seems a good time to wait for the conformation we hope will arrive from Scancell to deliver this wonderful expectation to the world which we have waited so long for better outcomes from this devastating disease
Thanks for posting this link Chelsea11.
I found it very useful. Providing clear and useful info, dates and duration times
I’m the first to give a 5star review for the new format for it’s ease of understanding. Please do the same if you find it useful
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-SCIB1-pembrolizumab-advanced-melanoma#undefined
JohnnyB1 great research as usual
Thank for the all the great work you do much appreciate
Helping me to stay more positive while we wait for some news which will hopefully move the SP up before we retate
Well done kash you are a shroud investor. I only wish I could be in profit at this time. Not sure what the repose of your post today was? But unhelpful and unrealistic for many LTH. Looking forward to hearing from you in Q4 23
Until the enjoy
LL. l’m very sorry to see you leave at this time. I think I understand your rational and making the decision to sell after a long time invested. I certainly hope your new venture works out well for you. I like many LTH are trying to figure out which sell / sells may of been yours, which I can’t figure out !!!!
Interesting article
https://www.fiercebiotech.com/biotech/takeda-weaves-f-star-tech-patchwork-cancer-capabilities-landing-license-bispecific-program
Come on Scancell show um what we got!!!
Wildforce, You say “ The best way to get real value for your science is prove it and then sell / deal with the highest bidders!
I think this has always been scancells aim ?”
The problem has been excuse after excuse as to why we have not delivered data yes Data. Other pharmas have managed it during even rolling out a Covid vaccine which has provided short term limited success, whilst scancell continued to develop a second generation Vaccine from a proven platform trialled in SA with 22 of the 40 trial patience’s we are still not producing the data that will encourage investors to invest. Our Cancer rollout which is wildly ambitious again 1 person enrolled.
“The science will not get us through”Only Data and meeting targets which have been set by the company will. I am aware deadlines can slip for many reasons but “under promising and over delivering “ works better. We seem to have a academic BOD with no Commercial driving force. Which may be address by Redmile. While all at the company continue to work with undeniable dedication and focus. We the pi’s feel very much in the dark and without the exceptional dedication of you and the group of dedicated BB heroes
Many would have fallen by the wayside.
Let’s hope the Broken PR machine spins into action or RNS to breath some life in the SP
Will we get an H1 update tomorrow (last day ) which will provide an update with regard to progress on all platforms, and any early data, and a focused expectation for H2
I hope for a positive information update/RSN
to take the company forward into an action packed H2
Burble, thank you so much for your latest mail and your unique way of explaining complex science in such a way many more investors understand the science with the compelling nuances. Scancell’s platforms address a vast breath of targets and memory to continue keeping patients safe.